Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07868489 phase 1/2 study in healthy adults and pulmonary arterial hypertension
jRCT2051240229Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing PF-07868489 with Placebo (2 arms). Primary endpoints: Number of participants with treatment-emergent adverse events and serious adverse events, Number of participants with change from baseline in laboratory test results and 3 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
PF-07868489
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2051240229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240229.